Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China

VernacularTitle:聚乙二醇干扰素α联合利巴韦林为基础的治疗方案在中国慢性丙型肝炎治疗中的临床价值
Author: Feng ZHU ¹ ; Qiongyue ZHANG ; Dazhi ZHANG
Author Information

1. 400010,重庆医科大学附属第二医院感染病科
Keywords: Hepatitis C,chronic; Interferon-alpha; Ribavirin; Direct-acting antiviral agents
From: Chinese Journal of Hepatology 2018;26(3):173-174,183
CountryChina
Language:Chinese
Abstract: Chronic hepatitis C virus (HCV) infection is one of the most common causes of liver cirrhosis and hepatocellular carcinoma in China.The older standard treatment regimen for chronic hepatitis C was the pegylated interferon-alfa plus ribavirin(PR).Now newer oral medications called direct antiviral agents (DAAs) has been gradually changed to PR-based DAAs and interferon-free,oral DAAs;making chronic hepatitis C a curable disease.This article intends to expound the advantages and disadvantages of PR-based therapy and provide reference for the treatment of chronic hepatitis C.